Drug intelligence / Profile preview

ST205

Development stage: Phase 1
Lead developer: Hangzhou Ruiao Biopharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ST205 is an antibody-drug conjugate (ADC) targeting Nectin-4, developed by Hangzhou Ruiao Biopharmaceutical. It consists of a humanized monoclonal antibody against Nectin-4 conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Nectin-4 is a cell surface protein highly expressed in various solid tumors, including bladder, breast, and lung cancers, while having limited expression in normal tissues. ST205 is being evaluated in clinical trials for the treatment of advanced solid tumors, both as a monotherapy and in combination with other agents such as ST114 (an anti-PD-L1 antibody).

Targets

PVRL4 (Nectin cell adhesion molecule 4)

Beyond the preview

Go deeper on ST205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST205.